Your browser doesn't support javascript.
loading
Segmental ureterectomy for high-risk ureteral carcinoma: a preliminary report.
Wei, Wei; Liu, Junfeng; Wang, Lingdian; Duan, Xiaoyu; Ding, Degang.
Afiliação
  • Wei W; Department of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China.
  • Liu J; Department of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China.
  • Wang L; Department of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China.
  • Duan X; Department of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China.
  • Ding D; Department of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China. 13503848199@163.com.
BMC Urol ; 23(1): 103, 2023 Jun 05.
Article em En | MEDLINE | ID: mdl-37277741
BACKGROUND: EAU guidelines strongly recommend kidney sparing surgery (KSS) as the primary treatment option for the low-risk UTUC patients. While there are few reports involving the KSS treated for the high-risk counterparts, especially the ureteral resection. OBJECTIVE: To evaluate the effectiveness and safety of the segmental ureterectomy (SU) for the patients with high-risk ureteral carcinoma. MATERIALS AND METHODS: We included 20 patients from May 2017 to December 2021 who underwent segmental ureterectomy (SU) in Henan Provincial People's Hospital. The overall survival (OS) and progression free survival (PFS) were evaluated. Besides, the ECOG scores and postoperative complications were also included. RESULTS: As of December 2022, the mean OS was 62.1months (95%CI:55.6-68.6months) and the mean PFS was 45.0months (95%CI:35.9-54.1months). The median OS and median PFS were not reached. The 3-year OS rate was 70% and the 3-year PFS rate was 50%. The percentage of Clavien I and II complications was 15%. CONCLUSION: For the selected patients with high-risk ureteral carcinoma, the efficacy and safety of segmental ureterectomy were satisfactory. But we still need to conduct prospective or randomized study to validate the value of SU in patients with high-risk ureteral carcinoma.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ureter / Neoplasias Ureterais / Carcinoma de Células de Transição Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: BMC Urol Assunto da revista: UROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ureter / Neoplasias Ureterais / Carcinoma de Células de Transição Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: BMC Urol Assunto da revista: UROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido